Loomis Sayles & Co. L P Trims Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Loomis Sayles & Co. L P decreased its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 31.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 417,208 shares of the biopharmaceutical company’s stock after selling 195,158 shares during the period. Loomis Sayles & Co. L P’s holdings in Agios Pharmaceuticals were worth $13,709,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new position in Agios Pharmaceuticals in the 4th quarter worth $33,000. Wingate Wealth Advisors Inc. purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at about $53,000. KBC Group NV raised its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares in the last quarter. Quest Partners LLC lifted its holdings in Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,283 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals during the 3rd quarter valued at approximately $146,000.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $30.28 on Friday. The company has a 50-day simple moving average of $33.17 and a two-hundred day simple moving average of $40.87. Agios Pharmaceuticals, Inc. has a 52-week low of $27.14 and a 52-week high of $62.58. The stock has a market capitalization of $1.73 billion, a PE ratio of 2.67 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on AGIO. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank upped their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 price target for the company. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $56.57.

Insider Activity

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.